Jefferies Group Reiterates “Buy” Rating for Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group in a report released on Friday.

Other research analysts have also issued reports about the company. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research report on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, November 15th. Barclays assumed coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price target for the company. Finally, Wedbush restated a “neutral” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research report on Monday, February 12th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $18.83.

Shares of Sangamo Therapeutics (NASDAQ SGMO) traded down $0.45 during trading on Friday, reaching $24.95. The company had a trading volume of 3,830,120 shares, compared to its average volume of 2,160,000. The stock has a market capitalization of $2,110.00, a price-to-earnings ratio of -35.14 and a beta of 2.87. Sangamo Therapeutics has a 52 week low of $3.65 and a 52 week high of $27.50. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $11.10 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm’s revenue for the quarter was up 46.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.14) earnings per share. equities research analysts predict that Sangamo Therapeutics will post -0.73 earnings per share for the current fiscal year.

In related news, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $18.49, for a total value of $92,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $16.13, for a total value of $268,241.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 84,953 shares of company stock valued at $1,544,843. Company insiders own 5.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of SGMO. Alexandria Capital LLC acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at $15,179,000. State Street Corp raised its stake in Sangamo Therapeutics by 51.6% in the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after buying an additional 636,296 shares in the last quarter. Vanguard Group Inc. raised its stake in Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares in the last quarter. American Century Companies Inc. acquired a new stake in Sangamo Therapeutics in the third quarter valued at $5,145,000. Finally, Tocqueville Asset Management L.P. raised its stake in Sangamo Therapeutics by 105.0% in the fourth quarter. Tocqueville Asset Management L.P. now owns 665,890 shares of the biopharmaceutical company’s stock valued at $10,921,000 after buying an additional 341,075 shares in the last quarter. Institutional investors own 68.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group Reiterates “Buy” Rating for Sangamo Therapeutics (SGMO)” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2018/02/23/jefferies-group-reiterates-buy-rating-for-sangamo-therapeutics-sgmo.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply